Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

· Issued by Arcturus Therapeutics Holdings Inc. via Business Wire

Summary by 6ix AI

Arcturus Therapeutics Holdings Inc., a messenger RNA (mRNA) medicines company developing treatments for rare liver and respiratory diseases, will take part in five investor conferences between September 8, 2026 and September 29, 2026.

Key details

  • Fireside chats: Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, 2026 at 2:15 p.m. ET; Citi's 2026 Biopharma Back to School Conference in New York on September 9, 2026 at 9:20 a.m. ET; Cantor Fitzgerald 12th Annual Global Healthcare Conference in New York on September 10, 2026 at 10:55 a.m. ET.
  • Presentation at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15, 2026 at 11:30 a.m. ET.
  • Investor meetings at the ROTH 5th Annual Healthcare Opportunities Conference in New York on September 29, 2026.
  • Webcast links are posted in the Investor Relations/Events section of the Arcturus website.

6ix AI wrote this summary from the release below and checked it against the release.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences:

Wells Fargo 21st Annual Healthcare Conference (Boston) | Fireside Chat

  • September 8, 2026 (2:15 p.m. ET)

Citi's 2026 Biopharma Back to School Conference (New York) | Fireside Chat

  • September 9, 2026 (9:20 a.m. ET)

Cantor Fitzgerald 12th Annual Global Healthcare Conference (New York) | Fireside Chat

  • September 10, 2026 (10:55 a.m. ET)

H.C. Wainwright 28th Annual Global Investment Conference (New York) | Presentation

  • September 15, 2026 (11:30 a.m. ET)

ROTH 5th Annual Healthcare Opportunities Conference (New York) | Investor Meetings

  • September 29, 2026

Webcast links can be found under Investor Relations/Events section of Arcturus’ website.

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus' strategic collaborations include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a Japanese joint venture focused on manufacturing mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.

View original source (Business Wire)Arcturus Therapeutics Holdings Inc. on 6ix

Story so far

Earlier from Arcturus Therapeutics

Later from Arcturus Therapeutics

All Arcturus Therapeutics news releases